Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Short Interest Up 88.8% in June

Posted by Paula Ricardo on Jul 18th, 2026

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC – Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 83,765 shares, an increase of 88.8% from the June 15th total of 44,358 shares. Based on an average trading volume of 30,721 shares, the days-to-cover ratio is presently 2.7 days. Approximately 8.4% of the company’s shares are sold short.

Virtus LifeSci Biotech Clinical Trials ETF Stock Performance

BBC opened at $50.97 on Friday. The business has a fifty day simple moving average of $46.47 and a 200-day simple moving average of $43.50. Virtus LifeSci Biotech Clinical Trials ETF has a 52 week low of $20.87 and a 52 week high of $54.95.

Institutional Trading of Virtus LifeSci Biotech Clinical Trials ETF

A hedge fund recently bought a new stake in Virtus LifeSci Biotech Clinical Trials ETF stock. Worth Asset Management LLC purchased a new stake in Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 4,093 shares of the company’s stock, valued at approximately $216,000. Worth Asset Management LLC owned approximately 0.41% of Virtus LifeSci Biotech Clinical Trials ETF at the end of the most recent reporting period.

Virtus LifeSci Biotech Clinical Trials ETF Company Profile

(Get Free Report)

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.